Leonard Philip James

机构：Pfizer (United States)

发表论文 39 篇 · 总被引 4821 次 · h-index 18

代表论文

• The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior (2000 · Annual Review of Cell and Developmental Biology · 被引 1357)
• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study (2018 · The Lancet Oncology · 被引 804)
• Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial (2017 · The Lancet Oncology · 被引 661)
• Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F (2015 · New England Journal of Medicine · 被引 490)
• Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer (2009 · Radiology · 被引 347)
• Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). (2014 · Journal of Clinical Oncology · 被引 258)